ZYMEWORKS INC. - COMMO

Zymeworks Announces Participation in Upcoming Investor Conferences

26 мар 2025 06:00:00 Источник Nasdaq GlobeNewswire

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

25 мар 2025 16:30:35 Источник Nasdaq GlobeNewswire

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

05 мар 2025 16:05:00 Источник Nasdaq GlobeNewswire

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

26 фев 2025 06:00:00 Источник Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

25 фев 2025 06:00:00 Источник Nasdaq GlobeNewswire

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

18 фев 2025 06:00:00 Источник Nasdaq GlobeNewswire

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

13 фев 2025 06:00:00 Источник Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

30 янв 2025 06:00:00 Источник Nasdaq GlobeNewswire

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

08 янв 2025 16:05:00 Источник Nasdaq GlobeNewswire

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

12 дек 2024 08:30:00 Источник Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

21 ноя 2024 06:05:00 Источник Nasdaq GlobeNewswire

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

21 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

05 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire

Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results

31 окт 2024 16:05:00 Источник Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

29 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

25 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

21 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

10 окт 2024 06:30:00 Источник Nasdaq GlobeNewswire

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

18 сен 2024 06:00:00 Источник Nasdaq GlobeNewswire

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

03 сен 2024 16:30:00 Источник Nasdaq GlobeNewswire